Concepedia
Statistics
Publications
24
Citations
1.2K
H-Index
16
Active since
2006
Affiliations
Cedars-Sinai Medical Center(Current)
The University of Texas at San Antonio Health Science Center
Seno Medical (United States)
Goethe University Frankfurt
Hôpital Beaujon
Fred Poordad is an author at Cedars-Sinai Medical Center specializing in pharmacy, antiviral therapy, and pharmacotherapy.
Publications per year
2006–2021
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 437 citations · Full text
Pharmacy, Infectious Diseases, Pharmacotherapy +17
1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
M.P. Manns, Patrick Marcellin, Fred Poordad et al. · Journal of Hepatology · 2013 · 122 citations
Pharmacy, Infectious Diseases, Pharmacotherapy +12
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
Eric Lawitz, Diane E. Shevell, Giridhar Tirucherai et al. · Hepatology · 2021 · 100 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +17
Screening for hepatitis B in chemotherapy patients: survey of current oncology practices
Thao Tran, Mina O. Rakoski, Paul Martin et al. · Alimentary Pharmacology & Therapeutics · 2009 · 59 citations
Medicine, Oncology, Cancer Screening +15
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
Ira M. Jacobson, Patrick Marcellin, Stefan Zeuzem et al. · Hepatology · 2012 · 51 citations
1–5 of 24